Earnings Call · Q1 FY2022·2022-05-12

Q1 22EPS -100.00%*·Rev n/aQ4 21EPS -78.95%·Rev n/aQ3 21EPS -84.62%·Rev n/aQ2 21EPS +28.57%·Rev n/a⚠ consensus missing

Eton Pharmaceuticals, Inc. ETON

David Krempa — Senior Vice President of Business Development

Sean Brynjelsen — Chief Executive Officer

James Gruber — Chief Financial Officer

−5.9%1d on move date−5.8% vs SPY3d+4.6%5d+3.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ETON calls or request research access.

More ETON calls Browse calls Request research access